Agreements reached under this partnership
Business alliance- 1
LABバイオテック will provide candidate lactic acid bacteria EVs.
- 2
The Company will leverage the evaluation technologies it has developed in the ophthalmology field to conduct efficacy and pharmacology studies and other tests, thereby assessing the potential of the EVs as treatments for ophthalmic diseases.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
There is no change to the earnings forecast for the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Name of alliance partner | 株式会社LABバイオテック |
| Alliance partner's business activities | A certified startup originating from Hokkaido University that conducts integrated operations from the exploration of novel lactic acid bacteria through commercialization. The company possesses 900 proprietary lactic acid bacteria strains and is advancing multiple lactic acid bacteria projects. It has established purification technology for lactic acid bacteria exosomes (EVs) and provides a diverse range of highly purified EVs derived from its proprietary lactic acid bacteria. |
| Alliance partner's location | Sapporo City, Hokkaido |
| Type of alliance | Business alliance |
| Details of the alliance | LABバイオテック will provide candidate lactic acid bacteria EVs., The Company will leverage the evaluation technologies it has developed in the ophthalmology field to conduct efficacy and pharmacology studies and other tests, thereby assessing the potential of the EVs as treatments for ophthalmic diseases. |
| Impact on Business Performance | There is no change to the earnings forecast for the fiscal year ending December 2026. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The parties believe this initiative will help expand the Company's pipeline by pursuing the development of ophthalmic drugs that leverage a new modality.